A Paps
YOU?
Author Swipe
The Development of a Multidisciplinary Care Pathway for Patients with Inflammatory Bowel Disease Before, During and After Pregnancy Open
Background/Objectives: Recent advancements have significantly enhanced our understanding of the interplay between inflammatory bowel disease (IBD) and reproductive health. While international organizations provide guidelines for best pract…
The development of a multidisciplinary care pathway for patients with inflammatory bowel disease before, during and after pregnancy Open
Background Recent advancements have significantly enhanced our understanding of the interplay between inflammatory bowel disease (IBD) and reproductive health. While international organizations provide guidelines for best practices, transl…
N16 Optimizing care for women of childbearing age with Inflammatory Bowel Disease: Developing a specific pathway utilizing European Crohn's and Colitis Organisation guidelines and the American Gastroenterology Association recommendations Open
Background Recent advances have greatly improved our understanding of the interaction between Inflammatory bowel disease (IBD) and reproductive health. The European Crohn's and Colitis Organisation (ECCO) and the American Gastroenterology …
P0739 Treatment persistence, clinical, and biological outcomes following an elective switch from intravenous to subcutaneous infliximab and vedolizumab Open
Background Subcutaneous (SC) formulations of infliximab (IFX) and vedolizumab (VDZ) are approved for treating ulcerative colitis (UC) and Crohn’s disease (CD). This study reports on treatment persistence, as well as clinical, biological an…
N07 JAKne: JAK inhibitor associated acne, a real-life single-center experience Open
Background Three Janus kinase (JAK) inhibitors, tofacitinib (TFC), filgotinib (FIL) and upadacitinib (UPA), have been approved for treatment of Crohn’s disease (CD) and/or ulcerative colitis (UC). During the IBD registrational trials, acne…
Profiling the Use of Complementary Alternative Medicines among Inflammatory Bowel Disease Patients: Results from a Single Center Survey Open
Background. Complementary and alternative medicines (CAMs) are used by patients with chronic disorders, such as inflammatory bowel disease (IBD), with a desire to manage their disease. Methods. Patients visiting an IBD outpatient clinic an…
N01 Type of patient education impacts the willingness to switch from an IV to SC of a biological in patients with Inflammatory Bowel Disease: A multicentre, comparative study Open
Background Subcutaneous (SC) formulations of CT-P13 and vedolizumab (VED) are currently available as new treatment option for patients with inflammatory bowel disease (IBD). The decision to switch requires a shared decision making based on…
P475 Profiling the use of Complementary Alternative Medicines among IBD patients Open
Background Inflammatory Bowel Disease (IBD) is a chronic inflammatory disease of the gut, characterized by multiple symptoms of which some cannot be successfully managed by existing conventional therapies. The use of complementary alternat…
N03 Information flow experiences during COVID-19 in IBD patients: a prospective observational study Open
Background During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, several patients contacted members of the IBD team with coronavirus disease 2019 (COVID-19) related questions. Some patients intended to cancel sc…